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1 
2 
3 Abstract 
4 
5 
6 
7 Introduction: Despite recent prognostic improvements, mantle cell lymphoma 
8 
9 (MCL) remains incurable. Bruton tyrosine kinase (BTK) is a key receptor in B-cell 
10 tumorigenesis, and the benefits of the first BTK inhibitor, ibrutinib, are becoming 
11 
12 clear in MCL. However, off-target activities, which contribute to ibrutinib-related 
13 
14 adverse events, suggest potential for further improvement of this drug class. 
15 
16 Areas covered: We systematically interrogated Clinicaltrials.gov for trials containing 
17 
18 keywords for BTK and MCL. Published literature for new and emerging BTK 
19 inhibitors being investigated in MCL was then identified (PubMed and Embase) and 
20 
21 summarized, and placed in the context of treatment guidelines. 
22 
23 Expert commentary: Reduced off-target effects of new and emerging covalent, 
24 
25 irreversible BTK inhibitors under investigation in patients with MCL offer the 
26 potential of improved safety compared with ibrutinib. Efficacy may also be favorable 
28 based on trial data for acalabrutinib, which has just been approved in the USA as 
29 
30 second-line therapy for MCL. The role of BTK inhibitors in treating MCL will evolve 
31 substantially over the coming years as results from a number of trials become 
32 
33 available, particularly in relation to potential upfront use and possible synergy with 
34 
35 other targeted therapies such as B-cell lymphoma 2, phosphoinositide 3-kinase and 
36 checkpoint inhibitors. 
37 
38 
39 
40 Keywords: Bruton tyrosine kinase inhibitors; B-cell malignancies; mantle cell 
41 lymphoma; efficacy; adverse events; treatment guidelines 
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1 
2 
3 1. Introduction 
4 
5 Mantle cell lymphoma (MCL) is classified by the World Health Organization as a 
6 B-cell neoplasm with morphological variants of diverse clinical behavior [1]. It is an 
7 
8 uncommon malignancy, accounting for around 6% of non-Hodgkin lymphoma (NHL) 
9 cases [2]. The incidence of MCL appears to be increasing [3,4], although this may be 
11 due to improved diagnosis rather than an increase in the actual frequency of the 
12 
13 disease. MCL most commonly occurs in men, with a median age at diagnosis of 68 
14 years [4]. Data support the presence of familial risk factors [5-8] and some 
16 environmental risk factors for MCL [6,9], but many associations with environmental 
17 
18 factors seen for other NHL types have not been observed for MCL [6]. Survival and 
19 relapse rates for MCL have recently improved with the incorporation of novel agents 
20 
21 and aggressive upfront therapeutic strategies [10,11]. However, with the possible 
22 exception of allograft, MCL is still incurable [12] and a substantial unmet need 
24 therefore remains. 
25 
26 
27 Bruton tyrosine kinase (BTK) is a kinase enzyme in the B-cell receptor pathway that 
29 is critical for the initiation, survival and progression of B-cell malignancies [13-15]. 
30 
31 The unique structure of BTK, which is characterized by a cysteine (Cys-481) within 
32 the ATP-binding pocket, has made it an attractive therapeutic target. The first 
33 
34 realization of this potential has already materialized with the development of 
35 ibrutinib. This first-in-class, irreversible, small-molecule inhibitor of BTK covalently 
37 binds to Cys-481 [16] and is indicated for use as second-line therapy in MCL in both 
38 
39 the USA (in patients who have received at least one prior therapy) and Europe (in 
40 relapsed or refractory disease), based on the positive results of a pivotal phase 2 trial 
41 
42 [17,18]. Not surprisingly, numerous additional indications are also being sought for 
43 
44 this drug in patients with MCL, including as front-line medication in combination 
45 with bendamustine plus rituximab (BR) (NCT01776840). 
46 
47 
48 The clinical benefits of ibrutinib in MCL and other B-cell malignancies are becoming 
50 increasingly clear. Nevertheless, the development of additional BTK inhibitors for 
51 
52 this disease is warranted owing to off-target inhibition of kinases by ibrutinib [16] that 
53 may contribute to the adverse events (AEs) associated with this molecule. These 
54 
55 include atrial fibrillation, bleeding, diarrhea, rash, headache and nausea [19-23]. 
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1 
2 
3 Indeed, data from patients with chronic lymphocytic leukemia (CLL) taking ibrutinib 
4 show that AEs are a common reason for treatment discontinuation.[24,25] Here we 
6 review the state of new and emerging BTK inhibitors under investigation in patients 
7 
8 with MCL, and discuss their potential placement in treatment guidelines. 
9 
10 
11 2. Materials and methods 
12 
13 Searches were conducted in Clinicaltrials.gov to identify trials with fields containing 
14 
15 key terms for BTK inhibitors (BTK OR Bruton OR Bruton’s OR Brutons) AND MCL 
16 (MCL OR  mantle). Filters  were applied to exclude studies that had been terminated or 
17 
18 withdrawn. It is possible that clinical trials not specifically mentioning MCL in either 
19 the ‘condition’ or ‘submitted keywords’ fields in Clinicaltrials.gov may include 
21 patients with MCL as part of a broader clinical trial population. However, for the 
22 
23 purpose of focusing this review, we considered an absence of MCL search terms to 
24 indicate a lack of intent by the investigator and/or manufacturer to move forward into 
26 MCL with their molecule. Searches were performed in PubMed (for full papers) and 
27 
28 Embase (for conference abstracts) to identify primary research articles with 
29 information on new and emerging BTK inhibitor molecules identified from the 
30 
31 Clinicaltrials.gov searches. The ‘hits’ from these searches were screened to exclude 
32 those with irrelevant study topics and study types (e.g. reviews). 
34 
35 
36 3. New and emerging BTK inhibitors in MCL 
37 
38 In total, 36 trials were identified on Clinicaltrials.gov that included search terms for 
39 BTK inhibitors and MCL. Of these, five were excluded because search terms were 
41 present in the introductory text but were not the focus of the clinical trial, and 21 were 
42 
43 excluded because they were investigating ibrutinib as the only BTK inhibitor. The 
44 remaining 10 trials were confirmed as assessing new and emerging BTK inhibitor 
46 molecules (acalabrutinib [ACP-196], BGB-3111, SNS-062, ARQ-531, M7583 and 
47 
48 CT-1530). Details of the ongoing clinical trials identified for the new and emerging 
49 BTK inhibitors under investigation in MCL are provided in Table 1. Data identified 
50 
51 from the targeted literature searches for each of these molecules are summarized 
52 below, with the exception of CT-1530 for which no published articles (full papers or 
54 conference abstracts) were identified. 
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1 
2 
3 3.1. Acalabrutinib (ACP-196) 
4 Acalabrutinib inhibits BTK by covalently and irreversibly binding to Cys-481. The 
6 IC50 value (concentration where the response is reduced by half) for acalabrutinib 
7 
8 against purified BTK is 5.1 nM compared with 1.5 nM for ibrutinib [26]. In cellular 
9 assays, EC50 values (concentration that gives the half-maximal response) for 
10 
11 acalabrutinib and ibrutinib for inhibition of B-cell receptor (BCR)-induced CD69 
12 expression are 2.9 nM and 0.58 nM, respectively, in peripheral blood mononuclear 
14 cells, with comparable results in human whole blood (9.2 nM and 5.8 nM, 
15 
16 respectively) [26]. The degree of inhibition of BCR-induced responses (BTK, S6 and 
17 ERK phosphorylation) is also similar for these molecules in primary CLL cells [27]. 
19 In mice, the ED50 value (dose where the measured effect occurs in at least 50% of 
20 
21 samples) for inhibition of CD69 expression in splenocytes was 1.3 mg/kg for 
22 acalabrutinib and 2.9 mg/kg for ibrutinib [26]. Pre-clinical anti-tumor effects have 
23 
24 been demonstrated for acalabrutinib in terms of reduced cell viability in large B-cell 
25 lymphoma cell lines [28], induction of apoptosis in primary CLL cells [27,29] and 
27 improved outcomes in a canine B-cell NHL model and two mouse CLL models 
28 
29 [30,31]. In healthy volunteers acalabrutinib is rapidly absorbed (Tmax [time to 
30 maximum plasma concentration of drug] of 0.5–1.0 hours), has a short half-life (T 
31 
32 [time required for elimination of 50% of drug from plasma] of 0.88– 2.1 hours), and 
33 
34 reaches full target occupancy with a single 100 mg dose [26]. Robust response rates 
35 have been reported with acalabrutinib in a phase 1/2 clinical trial in both relapsed or 
36 
37 refractory and untreated patients with CLL (NCT02029443) [32,33]. In this trial, the 
38 highest rate of BTK occupancy (98%) was observed with twice-daily dosing [33]. 
40 
41 
42 Acalabrutinib has fewer off-target effects than ibrutinib. In a panel of 395 non-mutant 
43 kinases, 1.5% were inhibited by at least 65% by 1 µM acalabrutinib, compared with 
44 
45 8.9% for 1 µM ibrutinib [26]. Acalabrutinib also has much lower activity than 
46 ibrutinib against kinases with a cysteine in the same position as BTK (TEC family 
48 kinases [ITK, TXK, BMX, TEC], EGFR, ERBB2, ERBB4, JAK3 and BLK) and SRC 
49 
50 family kinases (FGR, FYN, HCK, LCK, LYN, SRC and YES1) [26]. Indeed, IC50 
51 values for acalabrutinib were below 1000 nM (1 µM) for only four kinases other than 
53 BTK (ERBB4 [16 nM], BMX [46 nM], TEC [126 nM] and TKX [368 nM]), all of 
54 
55 which had substantially lower IC50 values in relation to ibrutinib (ERBB4 [3.4 nM], 
56 BMX [0.8 nM], TEC [10.0 nM] and TXK [2.0 nM]) [26]. Ibrutinib has been shown to 
½ 
57 
58 
59 
60 
29037715_File000005_680848898.docx 5 
URL: https://mc.manuscriptcentral.com/ehm Email: robert.middleton@tandf.co.uk 
 
5 
13 
18 
26 
39 
47 
52 
Page 5 of 22 Expert Review of Hematology 
 
 
1 
2 
3 also inhibit SRC, LCK and ITK far more potently than acalabrutinib in healthy T cells 
4 [27]. 
6 
7 
8 No cases of atrial fibrillation have been observed so far in the phase 1/2 clinical trial 
9 of acalabrutinib in the 61 patients with relapsed or refractory CLL, after a median 
10 
11 follow-up period of 14.3 months (NCT02029443) [32]. Although rates of atrial 
12 fibrillation in this study would be influenced by the exclusion of patients with 
14 significant cardiovascular disease and electrocardiogram abnormalities, significant 
15 
16 cardiovascular disease was also an exclusion criterion in an ibrutinib trial where cases 
17 of atrial fibrillation occurred in 10 out of 195 patients (5%) with relapsed or refractory 
19 CLL after a median follow-up of 9.4 months, of which six cases (3%) were grade 3 or 
20 
21 higher (NCT01578707) [21]. In another trial in patients with relapsed or refractory 
22 CLL, where the presence of electrocardiogram abnormalities was an exclusion 
23 
24 criterion, atrial fibrillation was reported as a serious AE in 3 (4%) of 85 patients 
25 (median follow-up: 20.9 months) (NCT01105247) [34]. In the phase 1/2 trial of 
27 acalabrutinib in CLL there have been no cases of atrial fibrillation with acalabrutinib 
28 
29 treatment in the 72 patients with treatment-naïve CLL, at a median follow-up of 11 
30 months (NCT02029443) [33]. In a trial of 136 patients with treatment-naïve CLL 
31 
32 receiving ibrutinib, 8 (6%) developed atrial fibrillation (1% were grade 3 or higher) at 
33 
34 a median follow-up of 17.4 months [35]. Both studies excluded patients with 
35 significant cardiovascular disease [33,35]. 
36 
37 
38 No cases of major hemorrhage have been reported in the phase 1/2 clinical trial of 
40 acalabrutinib in patients with relapsed or refractory (n = 61) or treatment naïve CLL 
41 
42 (n = 72) (NCT02029443) [32,33], with the exception of a single grade 3 gastric ulcer 
43 bleed due to aspirin use [33]. Clinical trials of ibrutinib have reported grade 3 or 
44 
45 higher bleeding in 5% (N = 85; median follow-up: 20.9 months [NCT01105247] [34]) 
46 and 1% (N = 195; median follow-up: 9.4 months [NCT01578707] [21]) of patients 
48 with relapsed or refractory CLL, and in 4% of patients with treatment naïve CLL (N = 
49 
50 136; median follow-up: 17.4 months [NCT01722487] [35]). The latter two studies 
51 [21,35] excluded patients taking warfarin and those with a history of intracranial 
53 hemorrhage. In a trial conducted in patients with CLL or small lymphocytic 
54 
55 lymphoma (N = 33) who discontinued ibrutinib (median treatment duration: 10.5 
56 months) owing to ibrutinib-attributable AEs, no major hemorrhage was reported with 
57 
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1 
2 
3 acalabrutinib treatment at a median follow-up of 9.5 months, including among six 
4 patients who previously developed bleeding events while on ibrutinib [22]. 
6 Acalabrutinib appears less likely to aggravate or precipitate AEs that lead to ibrutinib 
7 
8 discontinuation [22,23]. 
9 
10 
11 Headache has been more frequent in acalabrutinib CLL trials (42–43%) [32,33] than 
12 in ibrutinib CLL trials (14–18%) [21,34]. All cases of headache reported for 
14 acalabrutinib have been grade 1 or 2, have occurred early in treatment and have 
15 
16 generally resolved over time, and have not caused any patients to discontinue. 
17 Conversely, diarrhea and fatigue have been more common in ibrutinib CLL trials (42– 
19 49% and 28–32%, respectively [21,34,35]) than in acalabrutinib CLL trials (35–39% 
20 
21 and <15–21%, respectively [32,33]). However, acalabrutinib and ibrutinib have not 
22 been directly compared in any head-to-head clinical trials. Such data are necessary to 
23 
24 eliminate variations in study design between acalabrutinib and ibrutinib trials that may 
25 impact on observed differences in the rates of specific AEs. 
27 
28 
29 In October 2017, the Food and Drug Administration (FDA) approved acalabrutinib 
30 for use as a single agent in patients with relapsed or refractory MCL, based on the 
31 
32 positive results of a phase 2 study (NCT02213926: Table 1). In this trial, the overall 
33 
34 response rate (ORR) for acalabrutinib 100 mg given twice daily to patients with MCL 
35 (N = 124) was 81% (complete response in 40%) at a median follow-up of 15.2 months 
36 
37 (median duration of response, progression-free survival and overall survival were not 
38 reached) [36]. The ORR for ibrutinib 560 mg once daily in the pivotal trial that led to 
40 its approval in patients with relapsed or refractory MCL (N = 111) was 68% 
41 
42 (complete response in 27%) at a median follow-up of 15.3 months (NCT01236391) 
43 [18], although patients in this trial population were more heavily pre-treated and a 
44 
45 lower proportion (14%) had low-risk simplified Mantle Cell Lymphoma International 
46 Prognostic Index scores than in the acalabrutinib MCL trial (39%) [36]. 
48 
49 
50 The most common (≥ 20%) AEs in the acalabrutinib MCL trial were headache (38%), 
51 diarrhea (31%), fatigue (27%) and myalgia (21%) [36]. There were no cases of atrial 
53 fibrillation and only one serious (grade 3) bleeding event (gastrointestinal [GI] 
54 
55 hemorrhage in one patient with a history of a GI ulcer) [36]. In the ibrutinib MCL 
56 trial, the most common (≥ 20%) AEs were diarrhea (50%), fatigue (41%), nausea 
57 
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1 
2 
3 (31%), peripheral edema (28%), dyspnea (27%), constipation (25%), upper- 
4 respiratory tract infection (23%) and decreased appetite (21%) [18]. Serious AEs of 
6 atrial fibrillation occurred in five patients (5%) and grade 3 bleeding events also 
7 
8 occurred in five (5%) patients [18]. 
9 
10 
11 Acalabrutinib is also being investigated in combination with BR in patients with 
12 untreated MCL (NCT02717624 [phase 1] and NCT02972840 [phase 3]; Table 1), and 
14 in more ‘experimental’ combinations with the phosphoinositide 3-kinase inhibitor 
15 
16 ACP-319 (NCT02328014 [phase 1/2]) and the immune ‘checkpoint’ inhibitor 
17 pembrolizumab (NCT02362035). 
19 
20 
21 3.2. BGB-3111 
22 BGB-3111 is an irreversible BTK inhibitor [37,38]. The binding site for this molecule 
23 
24 has not (to our knowledge) been made publicly available. BGB-3111 inhibits BTK 
25 activity at unspecified nanomolar concentrations in biochemical assays and inhibits 
27 BCR-induced responses (BTK auto-phosphorylation and downstream PLCɣ2 
28 
29 signalling) in several MCL and diffuse large B-cell lymphoma cell lines [39]. BGB- 
30 3111 also has anti-proliferative effects and induces apoptosis in MCL cell lines, and 
31 
32 has similar anti-tumor activity to ibrutinib in a subcutaneous MCL xenograft mouse 
33 
34 model, but at a much lower dosage (2.5 mg/kg twice daily) versus ibrutinib (50 mg/kg 
35 once daily) [39,40]. 
36 
37 
38 In a phase 1 study in patients with relapsed or refractory B-cell malignancies, 
40 bioavailability of BGB-3111 80 mg once daily was similar to that for ibrutinib 
41 
42 560 mg once daily [37]. In addition, a mean 24 hour BTK occupancy of 98.6% was 
43 reported with BGB-3111 40 mg once daily, compared with greater than 90% 
44 
45 occupancy reported for acalabrutinib 200 mg once daily [41], which was itself 
46 reported as having better target coverage than ibrutinib 420 mg once daily. Of six 
48 patients in the phase 1 study who have MCL, four have had an objective response 
49 
50 (one complete response) after a median follow-up of 227 days [37]. 
51 BGB-3111 is reported as having greater selectivity than ibrutinib for BTK versus 
53 EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK, BLK and TEC, although 
54 
55 specific values were not able to be identified from the literature [37,39]. No drug- 
56 related serious AEs or AEs leading to discontinuation have been observed in the phase 
57 
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1 
2 
3 1 trial (N=25) of BGB-3111 in patients with relapsed or refractory B-cell 
4 malignancies, and no cases of grade 3 or 4 bleeding or of atrial fibrillation (including 
6 in four patients with a history of atrial fibrillation) have been reported [37]. 
7 
8 
9 Taken together, the above data indicate that BGB-3111 is a potent inhibitor of BTK, 
10 
11 with potentially better selectivity, bioavailability and target coverage than ibrutinib. 
12 There is one ongoing phase 2 trial of BGB-3111 in patients with relapsed or refractory 
14 MCL (NCT03206970; Table 1), but no data are yet available. Although not the focus 
15 
16 of the clinical trial searches, it is worth noting that a phase 3 trial comparing 
17 BGB-3111 to ibrutinib in patients with Waldenstrom Macroglobulinemia is ongoing 
19 (NCT03053440), and should provide useful information regarding the relative toxicity 
20 
21 of these two drugs. 
22 
23 
24 3.3. M7583 
25 
M7583 is an irreversible inhibitor of BTK. Where this molecule binds to BTK is not 
27 clearly described in the literature. Nevertheless, it has high potency, with an IC50 of 
28 
29 1.48 nM against purified BTK [42]. M7583 was found to inhibit six (2.2%) of a panel 
30 of 270 kinases by more than 50% (ZAP-70, BLK, BMX, TXK, ITK and SKG) at a 
31 
32 concentration of 1µM [42], which is comparable to the level of enhanced selectivity 
33 
34 exhibited for acalabrutinib versus ibrutinib (inhibition [≥ 65%] of 1.5% vs 8.9 of 395 
35 kinases, respectively, at a concentration of 1µM) [26]. 
36 
37 
38 M7583 is reported as having relatively low bioavailability of 16%, a short half-life of 
40 45 minutes, and a high (but unspecified) degree of BTK occupancy after dosing in 
41 
42 mice, and is currently being investigated in patients with relapsed or refractory B-cell 
43 malignancies in a phase 1/2 trial (NCT02825836; Table 1). At the time of reporting, 
44 
45 preliminary data from three subjects (one with MCL) enrolled in this trial showed that 
46 all had an objective response, or stable disease and a relevant clinical benefit [43]. 
48 
49 
50 3.4. SNS-062 
51 SNS-062 is a non-covalent (reversible) BTK inhibitor. The IC50 value for SNS-062 
53 against purified BTK is 2.9 nM [44], and this molecule has been shown to inhibit 
54 
55 BTK auto-phosphorylation in human whole blood and in mice [44]. In biochemical 
56 assays, SNS-062 exhibited binding to eight kinases at a concentration of less than 25 
57 
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1 
2 
3 nM, including BTK (0.3 nM) and the TEC kinase family member, ITK (2.2 nM) [44]. 
4 SNS-062 has been shown to decrease B-cell activation markers, viability and stromal 
6 cell protection in primary CLL cells [45]. Unlike ibrutinib and acalabrutinib, SNS-062 
7 
8 maintains its potent inhibitory activity against both wild-type BTK and cysteine 481 
9 to serine (C481S)-mutated BTK [44,45]. 
10 
11 
12 
SNS-062 is reported as having good oral bioavailability and tolerability in rats and 
14 dogs, with higher continuous drug levels and exposures than ibrutinib [44]. AEs 
15 
16 reported in a phase 1 trial of SNS-062 conducted in healthy volunteers included 
17 headache in 5 patients (25%) and nausea, bronchitis, fatigue, orthostatic hypotension, 
19 and supraventricular tachycardia in one patient (4%) each [46].There is one ongoing 
20 
21 phase 1/2 clinical trial for SNS-062 in patients with B-lymphoid malignancies 
22 (NCT03037645; Table 1). No data are yet available for this trial. 
23 
24 
25 
3.5. ARQ-531 
27 ARQ-531 is a reversible inhibitor of BTK and has an IC50 value of 0.85 nM [47]. 
28 
29 Treatment with ARQ-531 inhibits BCR-induced responses (BTK, AKT and ERK 
30 phosphorylation) in primary CLL cells [48]. However, this molecule demonstrates 
31 
32 off-target activity against a number of other kinases, including the majority of SRC 
33 
34 and TEC family kinases [48]. ARQ-531 exhibits better activity than ibrutinib in terms 
35 of reducing primary CLL cell viability and increasing survival times in a TCL1 mouse 
36 
37 model of leukemia [48]. In addition, ARQ-531 has similar IC50 values against both 
38 wild-type and C481S-mutated BTK [48]. Treatment with ARQ-531 also reduces the 
40 viability of primary CLL cells from patients with C481S-mutated BTK [48], and has 
41 
42 anti-proliferative activity against ibrutinib-resistant SUDHL-4 cells in tissue culture 
43 and a xenograft mouse model [47]. 
44 
45 
46 
In a single oral dose study conducted in monkeys, the bioavailability of 10 mg/kg 
48 ARQ-531 was 72.4% [48]. This molecule is being investigated in a phase 1 trial in 
49 
50 patients with hematological malignancies (NCT03162536; Table 1). No published 
51 data for this clinical trial were identified from our literature searches. 
53 
54 
55 4. BTK inhibitor pipeline in the context of MCL guidelines 
56 
57 
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1 
2 
3 Figure 1 shows the clinical development status of ibrutinib and new and emerging 
4 BTK inhibitors in MCL, in the context of National Comprehensive Cancer Network 
6 (NCCN) treatment guidelines [49], which are broadly similar to European guidelines 
7 
8 with regard to the use of BTK inhibitors [50]. So far, acalabrutinib is the only new 
9 BTK inhibitor to be approved in the USA for MCL. Like ibrutinib, this is in patients 
10 
11 who have received at least one prior therapy. All other new and emerging BTK 
12 inhibitors are being investigated exclusively in this setting. However, most ongoing 
14 clinical trials for acalabrutinib and ibrutinib are exploring experimental combinations 
15 
16 (in  less-aggressive  induction and second-line treatment settings)  with drugs not 
17 approved in MCL, for which data presumably support some synergy with BTK 
19 inhibitors, such as B-cell lymphoma 2 (BCL-2) inhibitors [51], programmed cell death 
20 
21 protein 1 (PD-1 [checkpoint]) inhibitors [52] and phosphoinositide 3-kinase (PI3K) 
22 inhibitors [53-55]. Only ibrutinib is being investigated in patients with MCL in the 
23 
24 aggressive induction setting and as a possible third-line treatment following 
25 bortezomib failure or relapse following donor stem cell transplant. 
27 
28 
29 5. Conclusion 
30 New and emerging BTK inhibitors have the potential to further optimize the treatment 
31 
32 of patients with this promising class of molecules. Placement of these drugs among 
33 
34 MCL treatment guidelines is likely to evolve substantially over the coming years, as 
35 safety and efficacy data from a number of ongoing trials exploring their potential 
36 
37 synergy with other drugs, particularly targeted therapies, become available. 
38 
39 
40 6. Expert commentary 
41 
42 The available evidence indicates that covalent, irreversible BTK inhibitors being 
43 investigated in patients with MCL (acalabrutinib, BGB-311 and M7583) may have 
44 
45 similar potency to ibrutinib, but with reduced off-target activity that could translate 
46 into improved safety and tolerability. Favourable clinical data for acalabrutinib raise 
48 the possibility that efficacy may also be enhanced, possibly as a result of more 
49 
50 complete and continuous inhibition of BTK due to its pharmacokinetic and 
51 pharmacodynamic properties, although no head-to-head data are available and 
53 therefore differences in the trial populations used may be a factor. The potential for 
54 
55 improved safety and tolerability seems less likely to apply to non-covalent, reversible 
56 BTK inhibitors being investigated in MCL (SNS-062 and ARQ-531), because these 
57 
58 
59 
60 
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1 
2 
3 molecules appear to have significant off-target activity against kinases that may be 
4 responsible for AEs associated with ibrutinib, including bleeding and atrial fibrillation 
6 [56-59]. Where the strengths of these molecules may lie is in their activity against 
7 
8 C481S-mutated BTK, although the clinical importance of this mutation in the 
9 development of ibrutinib resistance has recently been questioned. Nevertheless, other 
10 
11 advantages may well exist for these molecules that cannot be easily deduced from the 
12 currently available literature. Indeed, most of the available literature on new and 
14 emerging BTK inhibitors pertains to acalabrutinib. 
15 
16 
17 In any of the MCL treatment settings being investigated for ibrutinib, a BTK inhibitor 
19 with similar (or better) efficacy but an improved safety and tolerability profile would 
20 
21 represent an attractive alternative, providing (at the very least) an avenue to continue 
22 BTK inhibitor therapy in patients who would otherwise discontinue. AEs associated 
23 
24 with ibrutinib are a major impediment to achieving the best possible outcomes with 
25 this breakthrough class of molecules. This is particularly relevant to MCL, where the 
27 median age at onset is 68 years, meaning that the majority of patients will require less 
28 
29 aggressive induction therapy. Both ibrutinib and acalabrutinib are being investigated 
30 in phase 3 trials in this setting in combination with BR (NCT01776840 and 
31 
32 NCT02972840, respectively; Figure 1). 
33 
34 
35 Finally, it should be noted that, while data from single arm trials do indicate a more 
36 
37 favourable AE profile for acalabrutinib versus ibrutinib, no head-to-head data are yet 
38 available. Such data are important for addressing the potential effects of study design 
40 variation on observed safety profiles, such as exclusion criteria that could influence 
41 
42 rates of bleeding and atrial fibrillation with these drugs. To this end, an ongoing phase 
43 3 head-to-head study of ibrutinib and acalabrutinib in patients with relapsed or 
44 
45 refractory CLL (NCT02477696) will be particularly useful in cementing differences 
46 in the safety profiles of these drugs that have been hinted at in trials conducted to date. 
48 
49 
50 7. Five-Year View 
51 It is expected that several key trials in MCL will read out in the next year or two. This 
53 will include the use of BTK inhibition with BR versus BR alone (NCT01776840). If 
54 
55 positive, then BTK inhibition will be included in the upfront treatment of patients 
56 with MCL. The next logical question is whether the chemotherapy (bendamustine) 
56 
57 
58 
59 
60 
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1 
2 
3 component is required, or whether the addition of a CD20 antibody (rituximab) is 
4 sufficient. Early data from the MD Anderson Cancer Centre show a response rate of 
6 100% has been achieved when ibrutinib plus rituximab is used upfront. A UK trial 
7 
8 comparing rituximab-CHEMO  (Bendamustine  OR  CHOP [cyclophosphamide, 
9 doxorubicin,  vincristine  and prednisone]) with rituximab-ibrutinib as front-line 
10 
11 therapy for elderly patients is ongoing. If positive, chemotherapy-free treatment will 
12 become the new standard of care for elderly patients. In the relapse setting, BTK 
14 inhibition has been combined with BCL-2 inhibition (NCT02471391) and a 
15 
16 randomized phase 3 trial has started as well (NCT03112174). If positive, the BTK 
17 inhibitor plus BCL-2 inhibitor combination will be a new standard in relapsed or 
19 refractory MCL. It could then also be possible to have an upfront chemotherapy free 
20 
21 regimen in elderly patients that includes BTK inhibition plus BCL-2 inhibition plus 
22 anti-CD20 monoclonal antibody therapy. While no such trials are currently underway, 
23 
24 one might expected their initiation in the next few years. The field is truly exciting 
25 with novel agents having significant activity. 
27 
28 
29 8. Key issues 
30   Outcomes for patients with mantle cell lymphoma (MCL) have improved with 
32 the introduction of upfront aggressive and target therapies, but the disease 
33 
34 remains incurable with the possible exception of allograft. 
35   The clinical benefits of ibrutinib, the first Bruton tyrosine kinase (BTK) 
36 
37 inhibitor approved in MCL (as second-line treatment), are becoming clear, but 
38 
39 adverse events due to off-target effects warrant refinement of this drug class. 
40   The available literature suggests that new (acalabrutinib) and emerging (BGB- 
41 
42 3111, M7583) covalent, irreversible inhibitors under investigation in MCL 
43 have similar potency to ibrutinib, but with fewer off-target effects. 
45   Non-covalent, reversible BTK inhibitors under investigation in MCL (SNS- 
46 
47 062, ARQ-531) may not be as selective as covalent, irreversible inhibitors, but 
48 could have activity against some  ibrutinib-resistant B-cell  malignancies. 
50   Trials of acalabrutinib, which has now been approved in the USA as second- 
51 
52 line treatment for MCL, suggest that both safety and efficacy could be 
53 enhanced versus ibrutinib, although no head-to-head data are yet available. 
55 
56 
57 
58 
59 
60 
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1 
2 
3   Placement of BTK inhibitors in MCL treatment guidelines will likely evolve 
4 substantially over the coming years, as the results of trials exploring earlier use 
6 of these drugs (e.g. as less-aggressive induction therapy), and their potential 
7 
8 synergy with other targeted therapies, become available. 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
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3 
4 Table 1. Details of ongoing clinical trials of new and emerging Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma. 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
AE, adverse event; B-ALL, B-cell acute lymphocytic leukemia; BCL, B-cell lymphoma; BCM, B-cell malignancies; BCNHL, B-cell non-Hodgkin lymphoma; BOR, best 
32 overall response; BR, bendamustine + rituximab; CLL, chronic lymphocytic leukemia; DFCL, diffuse follicle center lymphoma; DLBCL, diffuse large B-cell lymphoma; 
33 DLTs, dose-limiting toxicities; HL, Hodgkin lymphoma; LL, lymphoplasmacytoid lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; MTD, maximum 
34 tolerated dose; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; ORR, overall response rate; PFS, progression-free survival; RP2D, recommended phase 2 
35 dose; R/R, relapsed or refractory; RS, Richter’s syndrome; SLL, small lymphocytic leukemia; TEAE, treatment-emergent adverse event; WM, Waldenstrom 
36 macroglobulinemia. 
37 
a Estimated primary completion date. 
38 
b MCL not specifically mention among listed conditions, but was included among keywords submitted for the study. 
39 
c Estimated enrolment number. 
40 
41 29037715_File000005_680848898.docx 20 
42 
43 
44 
45 URL: https://mc.manuscriptcentral.com/ehm Email: robert.middleton@tandf.co.uk 
46 
47 
Study ID Intervention Condition Phase Primary endpoint(s) N Completiona Approvals 
   
NCT02213926 Acalabrutinib R/R MCL 2 ORR (at least 1 year) 124 Feb 2017 FDA (Oct 2017) 
NCT02328014 Acalabrutinib + NHL, MM and B-ALLb 1/2 AEs (up to 1 year) 126c Aug 2017 None 
  ACP-319 
      
NCT02981745 CT-1530 R/R BCNHL, CLL, 1/2 DLTs (28 days) 200c Sep 2018 None 
 MCL, WM, MZL,  MTD and/or RP2D    
 DFCL and DLBCL      
NCT03037645 SNS-062 R/R CLL, LL, MCL, 
SLL and WM 
1/2 MTD and/or RP2D (up to 21 months) 
ORR (up to 24 months) 
124c Sep 2018 None 
NCT03206970 BGB-3111 R/R MCL 2 ORR (up to 3 years) 80c Nov 2018 None 
NCT03162536 ARQ-531 R/R BCL, DLBCL, 
SLL, CLL, MCL, WM 
1 AEs (up to 28 weeks) 
RP2D (up to 24 weeks) 
120c Dec 2018 None 
NCT02825836 M7583 R/R BCM, MCL and 
DLBCL 
1/2 DLTs (up to 28 days) 
BOR (up to 6 months) 
60c Oct 2019 None 
NCT02717624 Acalabrutinib + BR Untreated and R/R 
MCL 
1b TEAEs (timeframe unclear) 48c Feb 2021 None 
NCT02362035 Acalabrutinib + 
Pembrolizumab 
NHL, MM, HL, CLL, 
RS, WMb 
1b/2 TEAEs (2 years) 159 Apr 2021 None 
NCT02972840 Acalabrutinib + BR 
vs placebo + BR 
Untreated MCL 3 PFS (48 months) 546c Oct 2022 None 
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29 BR, bendamustine + rituximab; DSCT, donor stem cell transplant; L/R, lenalidomide/rituximab; NCCN, National 
30 Comprehensive Cancer Network; R-CHOP, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone; 
31 R-DHAP, rituximab + dexamethasone + cytarabine + cisplatin; R-DHAOx, rituximab + dexamethasone + cytarabine + 
32 
33 oxaliplatin 
34 a Includes treated and untreated patients. 
35 b MCL not specifically mention among listed conditions, but was included among keywords submitted for the study. 
37 c Malignancies other than MCL also included in the trial population. 
38 
39 
40 Figure 1. Trials of bruton tyrosine kinase (BTK) inhibitors in the context of National 
41 Comprehensive Cancer Network (NCCN) guidelines for the treatment of mantle cell lymphoma 
43 (MCL). New and emerging BTK inhibitors are highlighted in bold black text. Red text indicates 
44 
45 drugs that are being tested in combination with BTK inhibitors that are not currently recommended 
46 anywhere in NCCN treatment guidelines for MCL. Molecules within blue (rather than green) 
48 arrows are BTK inhibitors where there is reasonable evidence of enhanced BTK selectivity that 
49 
50 could translate into improved  safety and tolerability over  ibrutinib in an equivalent indication  under 
51 investigation. Clinical trials of new and emerging BTK inhibitors were identified from the results of 
52 
53 the initial ClinicalTrials.gov search (presented in Table 1). Clinical trials of ibrutinib were identified 
54 using a supplementary search for trials including terms for ibrutinib AND MCL. Unless otherwise 
56 indicated, trials are in patients with MCL only. 
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Figure 1. Trials of bruton tyrosine kinase (BTK) inhibitors in the context of National Comprehensive Cancer 45 
Network (NCCN) guidelines for the treatment of mantle cell lymphoma (MCL). New and emerging BTK 46 
inhibitors are highlighted in bold black text. Red text indicates drugs that are being tested in combination 47 
with BTK inhibitors that are not currently recommended anywhere in NCCN treatment guidelines for MCL. 
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Molecules within blue (rather than green) arrows are BTK inhibitors where there is reasonable evidence of 
enhanced BTK selectivity that could translate into improved safety and tolerability over ibrutinib in an 
equivalent indication under investigation. Clinical trials of new and emerging BTK inhibitors were identified 50 from the results of the initial ClinicalTrials.gov search (presented in Table 1). Clinical trials of ibrutinib were 
51 identified using a supplementary search for trials including terms for ibrutinib AND MCL. Unless otherwise 
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